CME Program
MDS Treatment Advances: Applying new data for decision-making
Order CD
Available after July 21, 2008
Program Description
Recent advances in both drug and transplant therapies provide new options for treating patients with myelodysplastic syndrome (MDS). Dr. Richard Stone will discuss novel drug agents and their potential application. Dr. Corey Cutler will discuss advances in transplantation and outcomes. From these two perspectives, the two paths will be compared, with patient eligibility defined for both. Using interactive case studies, they will also discuss their collaborative approach in defining a patient’s treatment strategy.Faculty
Corey Cutler, M.D. MPH FRCP(C)Assistant Professor of Medicine
Harvard Medical School
Department of Medical Oncology/Hematologic Malignancies
Dana-Farber Cancer Institute
Richard Stone, M.D.
Associate Professor of Medicine
Harvard Medical School
Department of Medical Oncology/Hematologic Malignancies
Dana-Farber Cancer Institute
Learning Objectives
- Describe application of newer drug therapies that may affect clinical practice
- Define the role and timing of transplantation in treatment decision-making
- Define patient eligibility in older patients for drug and transplant therapies, including the use of reduced-intensity regimens
- Describe the collaborative approach in working together to define a patient’s treatment strategy
Goal
The goal of this program is to enhance clinical decision-making through education on MDS therapeutic advances that affect patient eligibility.Target Audience
Physicians who treat patients for hematologic malignancies and who may refer for transplantation.Accreditation and Certification
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical College of Wisconsin and the National Marrow Donor Program® (NMDP). The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.The Medical College of Wisconsin designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
